ProjectCA209-76K: Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of MelanomaAfter Complete…
Basic data
Title:
CA209-76K: Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of MelanomaAfter Complete Resection of Stage IIB/C Melanoma (CheckMate 76K)
Duration:
01/01/2020 to 31/12/2027
Abstract / short description:
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab
versus Placebo after Complete Resection of Stage IIB/C Melanoma
(CheckMate 76K: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 76K)
versus Placebo after Complete Resection of Stage IIB/C Melanoma
(CheckMate 76K: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 76K)
Keywords:
melanoma
Melanom
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Thomas, Ioannis
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Brüssel, Belgium